Investor Relations Contacts

Sarah Cavanaugh
Senior Vice President
Corporate Affairs and Administration

email Email Investor Relations

Share Facebook Twitter Google+ LinkedIn

Press Releases

All Releases

Summary Toggle Celldex Therapeutics to Host Research and Development Day Highlighting Oncology Pipeline

Celldex Therapeutics to Host Research and Development Day Highlighting Oncology Pipeline 18.5 KB

Jan 18, 2012

Celldex Therapeutics to Host Research and Development Day Highlighting Oncology Pipeline NEEDHAM, Mass.--(BUSINESS WIRE)--Jan. 18, 2012-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it will host a research and development day for the investment community on Monday, January 23,
Read more
Summary Toggle Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301

Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301 19.6 KB

Jan 17, 2012

Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301 NEEDHAM, Mass. --(BUSINESS WIRE)--Jan. 17, 2012-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that dosing has initiated in a Phase 1 study of its hematopoietic growth factor, CDX-301, in healthy subjects.
Read more
Summary Toggle Celldex Initiates a Phase 2 Study of Rindopepimut in Patients with Recurrent Glioblastoma including Avastin® Naive and Refractory Populations

Celldex Initiates a Phase 2 Study of Rindopepimut in Patients with Recurrent Glioblastoma including Avastin® Naive and Refractory Populations 22.1 KB

Jan 4, 2012

Vaccine Targets Patients with EGFRvIII-positive Recurrent Glioblastoma

Read more

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

Our Pipeline